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The effects of ginsenoside Rb1 on endothelial
damage and ghrelin expression induced by
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Zhiwei Xu, PhD,a Taohua Lan, MD,a Weikang Wu, MD,a and Yiling Wu, PhD,b Guangzhou and
Shijiazhuang, Peoples Republic of China
Objective: Studies have indicated that ginsenoside Rb1 and ghrelin could both prevent homocysteine (Hcy)-induced endothelial
dysfunction through the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO)mechanism. This study investigated whether
endogenous ghrelin mediates the endothelial protection of ginsenosidee Rb1 through in vitro and in vivo experiments.
Methods: Rats were randomized into a control group, a hyperhomocysteine (HHcy) model group with a high methionine
diet, a ginsenosides (GS) group, and HHcy plus GS group. Plasma ghrelin was detected by enzyme-linked immunosor-
bent assay. Aortic rings for control and HHcy groups were treated with ghrelin or not. Endothelium-dependent
vasodilatation function was evaluated by the aortic ring assay, and the structural changes were visualized by hematoxylin
and eosin staining. Human umbilical vein endothelial cells (HUVECs) were cultured, and the experimental conditions
were optimized according to NO production. After treatment, the NO, ghrelin, and von Willebrand factor (vWF) levels
in the media were detected and analyzed with linear regression. Ghrelin and eNOS expression were observed by cell
immunohistochemical staining. Ghrelin receptor antagonist was used to detect the mechanism of ginsenoside Rb1 onNO
production, which was reflected by diacetylated 4,5-diaminofluorescein-2 diacetate fluorescence.
Results: In vivo experiments demonstrated that plasmaghrelin levels in theHHcygroupwere significantly elevated vs controls (P<
.05) and were significantly increased in the HHcy plus GS group (P < .01). Compared with control, endothelium-dependent
vasodilatation function was greatly reduced in the HHcy group (P< .01), which was significantly increased inHHcy plus ghrelin
group comparedwithHHcy group (P< .01). The arterial walls ofHHcy group exhibited characteristic pathologic changes, which
were repaired in HHcy plus ghrelin group. In vivo, compared with Hcy (200 M) group, HUVECs pretreated with ginsenoside
Rb1 (10 M) for 30 minutes showed significant increases in NO and ghrelin levels and evident reduction in vWF levels. Linear
regressionanalysisdemonstrated thatghrelin levelswere significantlypositively correlatedwithNOlevels andsignificantlynegatively
correlated with vWF levels. The addition of Rb1 to Hcy also greatly reversed Hcy-induced downregulation of ghrelin and eNOS
expression. Ghrelin inhibition significantly abolished the upregulation of NO levels induced by Rb1.
Conclusion:Ghrelin can prevent Hcy-induced vascular endothelial dysfunction and structural damage. The compensatory
elevation of plasma ghrelin levels in an Hcy-induced endothelial injury model may be a protective response. Ginsenoside
Rb1 can significantly stimulate the ghrelin endocrine to inhibit endothelial injury. Ginsenoside also upregulates the NO
signaling pathway reduced by Hcy through the ghrelin molecular mechanism. (J Vasc Surg 2011;53:156-64.)
Clinical Relevance:Homocysteine is an independent risk factor for endothelial injury and dysfunction. Ginsenoside Rb1, amajor
constituent of ginseng (traditional Chinese herb), can effectively block homocysteine-induced dysfunction of endothelium-
dependent vasorelaxation as well as endothelial nitric oxide synthase (eNOS) downregulation. Ghrelin, a novel brain-gut
peptide, has multiple cardiovascular protective effects, including vasorelaxation. The objective of this study was to determine
the effect and molecular changes of ginsenoside Rb1. Our results showed that ginseng compounds have effects of vasorelax-
ation and endogenous ghrelin upregulation. Exogenous ghrelin can block homocysteine-induced endothelial injury and
dysfunction in the rat thoracic aortic. Ginsenoside Rb1 can improve NO production, ghrelin, and eNOS expression in human
umbilical vascular endothelial cells. This study indicated that ginsenoside Rb1 has a prospective clinical future in controlling
homocysteine-associated vascular diseases through the ghrelin molecule and NO-signaling mechanism.
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Volume 53, Number 1 Xu et al 157Hyperhomocysteine (HHcy) is recognized as one in-
dependent risk factor for atherosclerosis. About 40% of
patients with coronary heart disease or cerebrovascular
atherosclerosis have hyperhomocysteinemia. Therefore,
prevention and treatment of atherosclerosis, calcification,
hypertension, and other chronic vascular diseases may lie in
the inhibition of excessive production of HHcy and allevi-
ation of its toxic effects on the vascular endothelium.
Ginseng is one of the most widely used traditional
Chinese medicines and is reported to have a wide range of
therapeutic and pharmacologic applications. Ginsenosides,
the major pharmacologically active ingredients of ginseng,
appear to be responsible for most of the activities of gin-
seng.1 In addition to influencing the central nervous sys-
tem, ginsenosides can be used in clinical endocrinology and
many cardiovascular and cerebral diseases because they
enhance NO release from endothelial cells.2,3 Ginsenosides
are also shown to have potential benefits on the cardiovas-
cular system through diverse mechanisms, including anti-
oxidant, modifying vasomotor function, reducing platelet
adhesion, influencing ion channels, altering autonomic
neurotransmitters release, improving lipid profiles, and in-
volving glucose metabolism.4
Our previous study used a high-methionine diet to
induce HHcy and establish an HHcy-induced endothe-
lial injury model in rats.5 Ginsenosides were adminis-
tered as a medication during establishment of the rat
model, indicating that ginsenosides can counteract the
effect of Hcy on endothelial injury and vascular vasodi-
latation function.6 The detailed mechanisms are still
unclear, however.
Ghrelin is a newly identified vasoactive peptide. It
functions as a paracrine/autocrine factor to maintain ho-
meostasis of the cardiovascular system and is important in
cardiovascular diseases.7,8 Ghrelin can prevent endothelial
cell death, increase the expression of nitric oxide (NO)
synthase in endothelial cells (eNOS), directly induce NO
synthesis, and protect endothelial functions, which can also
reverse Hcy-induced endothelial dysfunction in the porcine
coronary artery through regulation of the NO signaling
pathway.9 Data show that the ginsenoside monomer Rb1
can improve Hcy-induced porcine coronary artery dysfunc-
tion through regulation of the NO signaling pathway.10
Because the effects and mechanisms of ghrelin and
ginsenosides in endothelial protection are so similar, we
hypothesized that ginsenosides could protect against ho-
mocysteine-induced endothelial injury by mechanisms in-
volved in ghrelin induction and activation and in the
upregulated NO signaling pathway. In this study, we inves-
tigated the effects and molecular mechanisms of endothe-
lium protection by the ginsenoside monomer Rb1. This
study suggests a potential clinical application of ginsenoside
Rb1 and ghrelin in controlling Hcy-associated vascular
injuries, and provides a thought of seeking both a tempo-
rary solution and permanent cure in clinical vascular dis-
eases.MATERIALS AND METHODS
Chemicals and reagents. Total ginsenosides and the
ginsenoside monomer Rb1 (Rb1) were provided by Yiling
Pharmaceutical Industry Ltd Co (Shijiazhuang, China).
M199 media, trypsin, and fetal bovine serum were purchased
from Gibco (Invitrogen, Carlsbad, Calif). Endothelial cell
growth supplement was purchased from BD Biosciences (San
Jose, Calif). L-type methionine, succinylsulfathiazole (SST)
and Hcy were purchased from Sigma (St Louis, Mo).
Diacetylated 4,5-diaminofluorescein-2 diacetate (DAF-2
DA) was purchased from Cayman Chemical Co (Ann Ar-
bor, Mich). Ghrelin polypeptide and its receptor antago-
nist, [D-Lys3]-GHRP-6 was purchased from Phoenix
Pharmaceuticals Inc (Burlingame, Calif). The ghrelin
enzyme-linked immunosorbent assay (ELISA) kit was pur-
chased from Shanghai Shellgene Biotech Co, Ltd (Shang-
hai, China). The nitric oxide (NO) testing kit was obtained
from the Nanjing Jiancheng Biotechnology Institute (Nan-
jing, China). The ELISA kit for von Willebrand factor
(vWF) was purchased from Shanghai Taiyang Biotech Co,
Ltd (Shanghai, China). The primary antibodies for eNOS
and ghrelin and the streptavidin-biotin complex (SABC)
immunohistochemistry kit were purchased from Wuhan
Boster Biological Technology Co, Ltd (Wuhan, China).
Endothelial injury model and grouping. Male Wistar
rats (200-250 g) were obtained from the Experimental
Animal Center of Sun Yat-sen University (Clean grade,
Certificate No SCXK2004-0011) and randomly assigned
for the experiments. Animal use was in accordance with the
Chinese Council on Animal Care Guidelines. The HHcy-
induced endothelial dysfunction model was made using
intragastric administration of methionine as described pre-
viously.11 In HHcy group and HHcy plus ginsenosides
(GS) group, rats were intragastrically administered 1
g/kg/day L-methionine and supplied with drinking water
containing 0.5 g/kg succinylsulfathiazole for 4 weeks.
Then, rats in HHcy plus GS group were administered 1.2
g/kg ginsenoside for 7 days, whereas rats in control group
were administered equal volumes of double-distilled H2O
and supplied with drinking water without succinylsulfathi-
azole. After treatment, all rats were fasted overnight, and
blood samples were collected the next morning. After
anesthesia, blood samples were collected by cardiac punc-
ture into ethylenediaminetetraacetic acid-coated anticoag-
ulant tubes, mixed with aprotinin (0.6 TIU/mL blood
sample), and centrifuged at 4°C, 1600g for 15 minutes to
separate plasma. Samples were preserved at 80°C before
detection of ghrelin.
Thoracic arteries from control and HHcy groups were iso-
lated, placed in modified Kerbs solution (118 mmol/L NaCl,
4.7 mmol/L KCl, 216 mmol/L CaCl2, 1.2 mmol/L
MgSO4·7H2O, 112 mmol/L KH2 PO4, 25 mmol/L
NaHCO3, 5.5 mmol/L glucose, pH 7.4) and aerated with a
mixture of 95% O2 and 5% CO2. After dissociating the
surrounding fat and connective tissues carefully, each artery
was truncated into 3-mm-thick rings and incubated in a
37°C water bath. Then the aortic rings from control and
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out ghrelin (final concentration: 106M) for 1 hour. Finally,
a portion of aortic rings was examined histologically with
hematoxylin and eosin (HE) staining as reported,12 the
remaining portion of the aortic ring was kept in Krebs
solution for the vascular ring experiment.
Thoracic aortic ring relaxation assay. Endothelium-
dependent vasodilation function was detected as previously
described.13 These aortic rings were put into 4 mL Krebs
solution. Each aortic ring was transfixed with two L-shape
stainless steel hooks, with one fixed at the bottom of the
thermostatic tank and the other connected to a tension
transducer (JZ101) by a thread. Data were recorded with
the PowerLab system. The Krebs solution was aerated with
a mixed gas containing 95% O2 and 5% CO2, and the
solution was replaced every 20 minutes. The temperature in
the tank was maintained at about 37°C. The rings were
allowed to equilibrate for 1.5 hours after being subjected to
a tension of 1.5 g. The contraction signal was transmitted
through an 8-channel connector of MP-285 Micromanip-
ulator GSys to a personal computer that was connected to a
PowerLab system (ADInstruments Inc, Colorado Springs,
Colo). The data were recorded and analyzed with the
PowerLab system and its software, Chart.
Before this experiment, vessels were contracted with
0.1 mol/L KCl. If the difference between two consecutive
contraction amplitudes was10%, the vessel reactions were
considered repeatable; otherwise, the vessels were dis-
carded. During the following experiment, the vessels were
thoroughly washed after each step, and then the next step
was performed until the contraction signals curve returned
to baseline and stabilized for 25 minutes.
The vessel rings were precontracted in a high-
potassium solution, washed, and normalized to the baseline
level. Then the rings were soaked in 4 mL Krebs solution
supplemented with 40L phenylephrine (final concentration:
106 mol/L). After the contraction reaction reached a pla-
teau, the rings were treated with a range of cumulative con-
centrations of acetylcholine (1010 to 106 mol/L). The
relaxation percentages of vessel rings under different concen-
trations of acetylcholine were recorded, and acetylcholine-
induced endothelium-dependent vascular relaxation was
monitored.
Human umbilical vein endothelial cells culture and
grouping. Human umbilical cords were provided by the
Maternity Department at the Second Affiliated Hospital of
Sun Yat-sen University. This study was approved by the Eth-
ical Committee of Sun Yat-sen University Medical Faculty and
by the mothers whose umbilical cords were donated for
human umbilical vein endothelial cells (HUVECs). Fresh
umbilical cords were washed with phosphate-buffered sa-
line (PBS) in a cell culture hood to remove blood and residual
blood clots, and digested with 0.25% trypsin containing eth-
ylenediaminetetraacetic acid. HUVECs were collected by
low-speed centrifugation, resuspended, and seeded onto cell
culture flasks, plates, or dishes that were precoated with 0.2%
gelatin. Cells were maintained in Roswell Park Memorial
Institute medium 1640 containing 15% inactivated fetal calfserum, 100 U/mL penicillin, 100 U/mL streptomycin, and 2
mmol/L L-glutamine. Endothelial cell growth supplements
and 0.005 U/L heparin were added. The culture media was
changed every 2 days. Cells were passaged 2 to 3 days after
reaching 80% confluence. HUVECs were harvested, and
cell type was confirmed by vWF immunofluorescent posi-
tive staining with negative controls.
The third-generation HUVECs were seeded and incu-
bated with endothelial cell growth supplement until reach-
ing 90% confluence. HUVECs were divided into the fol-
lowing groups: control, Hcy-induced endothelial injury
groups (stimulated with 50, 100, 200, 300, or 500 M
Hcy), a dose range of ginsenoside monomer Rb1 plus Hcy
groups (pretreatment with 0.01, 0.1, 1, 10, or 100 M
Rb1 before Hcy stimulation), and a time-course of ginsen-
oside Rb1 plus Hcy groups (pretreatment for 5, 15, 30, or
60 minutes Rb1 before Hcy stimulation). The NO levels in
the culture media were detected 48 hours after the treat-
ment, and the model optimization for the following exper-
iments were established accordingly. Then HUVECs were
incubated for 48 hours with Hcy (200 M), Rb1 (10 M),
or Hcy plus Rb1. After treatment, cell culture media were
collected and preserved at 80°C before the detection of
NO, ghrelin, and vWF levels. HUVECs were fixed and
examined with immunohistochemical staining for intracel-
lular ghrelin and eNOS expression.
Detection of biochemical indices in blood and cul-
ture media. Ghrelin levels in plasma and the culture media
and vWF content in the culture media were detected with a
double-antibody ELISA. The NO level in the culture me-
dia was analyzed with the nitrate reductase assay, which
involves nitrate reductase deoxidization of NO3
 to
NO2
. The NO level can be calculated by measuring the
NO2
 concentration, as detected by chromometry. All
assays were performed according to the manufacturer’s
instruction of each kit.
Cell immunohistochemistry and detection of intra-
cellular NO content by fluorescent microscopy. After
treatment, cells were washed and incubated with anti-eNOS
or antighrelin primary antibody and the corresponding sec-
ondary antibodies. A group of negative controls was used in
each experiment, for which the primary antibody was replaced
with PBS. Finally, the coverslips were developed in 3,3=-
diaminobenzidine reagent and observed under the light mi-
croscope for the subcellular localization of each protein. The
protein levels were determined by semiquantitative analysis.
To detect intracellular NO production, HUVECs were
added with DAF-2 DA. This dye is hydrolyzed intracellu-
larly by cytosolic esterases releasing DAF-2, which can be
converted into a fluorescent product (DAF-2T) by NO.
The DAF-2 DA was loaded at a concentration of 1mol/L
in Krebs solution in the dark at 37°C for 30 minutes as
reported.14 Then cells were washed twice with PBS and
images were viewed and scanned by a Fluoview fluorescent
microscope (Olympus, Tokyo, Japan) at 485-nm excitation
wavelength and 530-nm emission wavelength for DAF-2
DA fluorescence. The green fluorescent densities were cal-
culated lastly.
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mean  standard deviation and analyzed with SPSS 11.0
software (SPSS Inc, Chicago, Ill). Two-sided t tests were
performed for the data between treatment and control
groups. One-way analysis of variance (ANOVA) was used
in a multigroup comparison of the measured data. The
correlations among NO, ghrelin, and vWF levels in the
culture media of HUVECs were determined by linear
regression. A value of P  .05 was considered statistically
significant.
RESULTS
Changes in aortic ring relaxation function. Comp-
ared with the control, the endothelium-dependent relax-
ation function was significantly reduced in the HHcy group
(P  .01; Fig 1). Compared with the HHcy group, the
percentage of aortic ring relaxation was significantly in-
creased in Hcy plus ghrelin group (P  .01), suggesting
that ghrelin can prevent the aorta from undergoing endo-
thelial dysfunction induced by HHcy. The endothelium-
dependent relaxation function of the aortic rings with a
Fig 1. Effects of hyperhomocysteine (HHcy) and ghrelin on the
rat aortic vasodilatation.A,The control and HHcy-induced model
aortic rings were truncated and incubated in Krebs solution with or
without ghrelin (106 M). There was significant difference in
maximum vessel contraction in response to a range of acetylcholine
(Ach, 1010 to 106 mol/L) among all groups (n 8). Mean data
are shown with the standard deviation. B, The contraction signals
curve relaxations of aortic rings were monitored, and the percent-
age of vasodilatation was recorded and analyzed. *P .05, **P
.01 vs control group; #P  .05, ##P  .01 vs HHcy group.high dose of acetylcholine (106 mol/L) was also signifi-cantly increased in the ghrelin group compared with the
control group (P  .05).
Pathologic changes in aortic structure. After treat-
ment, the aortic rings from rats in each group were fixed
and analyzed with pathologic examinations. The arterial
walls from the rats in the control group (Fig 2, a-c) and the
ghrelin group (Fig 2, j-l) did not show any abnormal
changes. However, rat vessels in the HHcy group (Fig 2,
d-f) were easily disrupted, and endothelium was extruded
and disconnected by lipid plaque. The elastic membrane
was severely distorted, and some vascular smooth muscle
cells underwent necrosis as demonstrated by deeply stained
cytoplasm and condensed nuclei. In addition, surrounding
connective tissues were infiltrated with granulocytes and
monocytes, whereas ghrelin treatment reduced the HHcy-
induced vascular injury and improved the vessel wall resto-
ration in the HHcy plus ghrelin group (Fig 2, g-i).
Changes in plasma ghrelin levels. After treatment,
the endogenous plasma ghrelin levels were detected by
ELISA in the four groups. Compared with the control
group, the endogenous plasma ghrelin level was upregu-
lated in the HHcy group (P .05), and compared with the
control and HHcy groups, the plasma ghrelin level was
significantly increased in the HHcy plus GS group (P 
.01, P  .05; Fig 3). Ginsenoside alone did not affect the
endocrine level of ghrelin in the GS group.
Primary culture and identification of HUVECs.
Using an inverted microscope or phase-contrast microscopy,
endothelial cells were visualized as flat, short spindle or poly-
gon shapes with uniform cell size and clear nuclei. HUVECs
were identified by indirect immunofluorescent staining with a
vWF antibody. Primary and passaged cultures of endothelial
cells were stained with yellowish-green fluorescent staining in
the cytoplasm and dark green in the nuclei, showing a clear
outline. Green spots without any cell outline were occasionally
seen in the negative control (data not shown).
Determination of optimal conditions for Hcy-
induced HUVECs injury. HUVECs were treated with a
range of Hcy concentrations, and the NO content in the
culture media was measured by the nitrate reductase assay.
Compared with the control group, NO levels in the 200
M Hcy group and 300 M Hcy group for 48 hours were
significantly reduced (P  .05), with 200 M Hcy group
showing the most significant reduction (Fig 4, A). Then,
cells were pretreated with a range of ginsenoside Rb1 doses
for 30 minutes before Hcy stimulation. The NO content
was significantly increased in the 10 M ginsenoside Rb1
pretreatment group compared with the Hcy group (P 
.05, Fig 4, B). Cells were also pretreated with ginsenoside
Rb1 before Hcy stimulation over a time-course. The results
demonstrated that NO levels were increased in the Hcy
plus ginsenoside Rb1 (pretreatment for 30 or 60 minutes)
groups significantly than in the Hcy group (P  .05), and
the Hcy plus Rb1 (pretreatment for 30 minutes) group
illustrating the most significant increase. Therefore, 30
minutes was set as the optimal pretreatment time for Rb1 in
the following experiments (Fig 4, C).
obvio
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culture media of HUVECs and correlation analyses of
different factors. As reported in the Table, compared with
Fig 2. Effects of hyperhomocysteine (HHcy) and ghreli
of the four groups were examined for evidence of patho
Panels a, b, and c show the control group; d, e and f, th
j, k, and l, the ghrelin group. Panels a, d, g, and j are
magnification 100; and c, f, i, and l are at original m
arrows show the foam cells of aorta lipid plaque and fra
improved endothelium in HHcy  ghrelin group. l, No
Fig 3. Effects of hyperhomocysteine (HHcy) and total ginsen-
osides (GS) on the plasma ghrelin levels in rats. After ginsenoside
treatment, the plasma ghrelin levels of the four groups were
detected by enzyme-linked immunosorbent assay. *P  .05,
**P  .01 vs control group; #P  .05 vs HHcy group. Mean data
are shown with the standard deviation.the control group, NO and ghrelin levels in the culture mediaof HUVECs were significantly decreased (P  .01), and the
vWF level was significantly elevated in the Hcy group (P 
.01). Compared with the Hcy group, NO and ghrelin levels in
the culture media of HUVECs were significantly increased
(P  .01, P  .05), and the vWF level was significantly
reduced in the Hcy plus Rb1 group (P .05). Linear regres-
sion indicated that the ghrelin level was significantly and
positively correlated with the NO level (r 0.71,P .01, Fig
5, A), whereas it was significantly and negatively correlated to
the vWF level (r0.55, P .05, Fig 5, B).
Cell immunohistochemical analysis of ghrelin and
eNOS expressions in HUVECs. The protein expression
levels of ghrelin and eNOS are shown in Fig 6, A and B,
respectively. The positive signal was defined as brownish-
yellow particles in the cytoplasm and/or nuclei. No positive
he aortic endothelial injury and restoration. Aortic walls
changes using routine hematoxylin and eosin staining.
cy group; g, h, and i, the HHcy  ghrelin group; and
iginal magnification 40; b, e, h, and k are at original
cation 400. c, Aortic wall structure is normal. f, The
endothelium in the HHcy group. i, The arrows show
us pathologic changes were observed in ghrelin group.n on t
logic
e HH
at or
agnifi
cturedsignal was detected in the negative control cells. As shown
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stained brown-yellow in the cytoplasm, implying that en-
dothelial cells had a high level of ghrelin expression. As
shown in Fig 6, B-b, cells in the control group were stained
with brownish-yellow particles in the cytoplasm and nuclei,
indicating that endothelial cells had a high level of eNOS
expression. Compared with the control group, ghrelin and
Fig 4. Effects of homocysteine (Hcy) and ginsenoside Rb1 (Rb)
on the nitric oxide (NO) levels in the culture media of human
umbilical vein endothelial cells (HUVECs). A, The NO levels in
the culture media of HUVECs treated with a range of Hcy doses
for 48 hours (Hcy, 50-500 M). B, The doses effects on NO
release into the culture media by ginsenoside Rb1 pretreatments
(0.01-100M, 30 minutes) plus Hcy (200M) stimulation for 48
hours. C, The time-courses effects on NO release into the culture
media by ginsenoside Rb1 pretreatment (10 M, 5-60 minutes)
plus Hcy (200 M) for 48 hours. *P .05 vs control group; #P
.05 vs Hcy 200 M group. Mean data are shown with the standard
deviation.
Table. The impacts of homocysteine (Hcy) and Rb1 on
nitric oxide (NO), ghrelin, and von Willebrand factor
(vWF) levels in the culture media (n  6)
Groups
NO (uM/L) Ghrelin (ng/mL) vWF (%)
Mean  SD Mean  SD Mean  SD
Control 121.7  10.37 14.18  0.9949 103.1  10.02
Hcy 100.0  9.844a 11.65  1.525b 159.2  13.32b
Hcy  Rb1 137.5  12.55c 13.69  1.254c 137.9  12.57c
aP  .01 vs control group; bP  .05; cP  .01 vs Hcy group.eNOS signals were weakened in the Hcy group (P  .01,Fig 6, A-c and B-c), whereas ghrelin and eNOS signals were
both significantly increased in the Hcy plus Rb1 group
compared with the Hcy group (P  .01, Fig 6, A-d and 6,
B-d). The expression levels of ghrelin and eNOS were
further analyzed with a cell image analysis system. Semi-
quantitative analysis indicated that Rb1 significantly up-
regulated ghrelin and eNOS expression levels that were
down regulated by Hcy (Fig 6, C).
The effects of ghrelin inhibition on NO prod-
uction. Fluorescence images are shown in Fig 7, A. The
intracellular fluorescence intensity in the Hcy group (Fig 7,
A-b) was significantly reduced compared with the control
(Fig 7,A-a). Analysis of mean fluorescence intensity of Hcy
group and Hcy plus Rb1 group (Fig 7, A-d) confirmed a
significant increase of NO content in response to Rb1. One
hundred micromoles of [D-Lys3]-GHRP-6,15 ghrelin re-
ceptor antagonist plus Rb1 was added 30 minutes before
Hcy stimulation, then intracellular NO content was also
detected. Rb1 group (Fig 7, A-c) and ghrelin receptor
antagonist group (Fig 7, A-f) had no effect on NO produc-
tion, but the ghrelin receptor antagonist significantly abol-
ished the increase of NO production induced by ginsen-
oside Rb1 in Hcy plus Rb1 plus ghrelin receptor antagonist
group (Fig 7, A-e).
DISCUSSION
Our study showed that exogenous ghrelin can prevent
Hcy-induced vascular endothelial dysfunction and struc-
tural damage. The compensatory elevation of plasma en-
dogenous ghrelin level in an HHcy-induced endothelial
injury model may be a protective response against injury in
rats. We also showed that ginsenoside Rb1 prevented Hcy-
induced impairment of endothelium-dependent vasodilata-
tion and improved Hcy-induced reduction of NO produc-
tion. To our knowledge, this is the first study that shows
ghrelin molecule and NO mechanism mediated the protec-
tive effects of ginsenosides on endothelium and ginsen-
oside Rb1 on HUVECs. Our results suggest the potential
clinical application of ginsenosides in prevention of HHcy-
Fig 5. The correlations are shown among nitric oxide (NO),
ghrelin, and von Willebrand factor (vWF) levels. Human umbilical
vein endothelial cells were incubated for 48 hours with homocys-
teine, or homocysteine plus Rb1, and then the culture media were
collected for detection. A, The correlation between NO and
ghrelin levels in the culture media was analyzed by linear regression
(r 0.71, P .01). B, The correlation between vWF and ghrelin
levels in the culture media was analyzed by linear regression (r 
0.55, P  .05).associated cardiovascular disease.
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myocardial infarction, stroke, and vascular diseases. It was
found that prolonged exposure of endothelial cells to Hcy
impaired the production of endothelium-derived relaxing
factor NO.16 Hcy can also significantly impair endothelium-
dependent vasodilatation function and inhibit the activity of
eNOS by reducing Arg transport17 and activating protein
kinase C.18 This study established an endothelial injury
Fig 6. Effects of homocysteine (Hcy) and ginsenoside Rb1 is
shown on ghrelin and endothelial nitric oxide synthase (eNOS)
immunoreactivity in human umbilical vein endothelial cells
(HUVECs). A and B, HUVECs were incubated for 48 hours with
Hcy, or Hcy plus Rb1, and then intracellular ghrelin and eNOS
protein levels (brown-yellow staining signal) were determined with
immunohistochemical staining. Panel a, negative; b, control
group; c, Hcy group; d, Hcy Rb1 group; original magnification
200. C, The staining signal was analyzed by grayscale scanning
use the image analysis system. **P  .01 vs control group; ##P 
.01 vs Hcy group. Mean data are shown with the standard
deviation.model with a wide dose range of Hcy (50–500 M Hcy) asreported,19 and these doses crossed and represented the
different severity degrees of clinical HHcy. Our results
demonstrated that Hcy can suppress endothelium-depen-
dent vasodilatation function, inhibit eNOS expression and
NO production, and induce vWF release, a key parameter
and biomarker of endothelial injury.20
There is increased clinical evidence concerning the
potential benefits of ginseng in cardiovascular diseases.
Studies show that ginsenosides may prevent vascular injury
and dysfunction through inducing NO release.21,22 Gin-
senosides can enhance the activity of calcium-activated
potassium ion channels in vascular smooth muscles and
increase the opening rate of the Ca2-activated K chan-
nels (KCa) on the endothelial cell membranes.23 Our pre-
vious study also showed that the Chinese herbal medicine
ginseng and its ginsenoside extracts can both prevent Hcy-
induced endothelial injury.6 The ginsenoside Rb1 pos-
sesses potent pharmacologic activity toward the cardiovas-
cular system, which has been proven to increase NO
production in the vascular endothelium3,24 and ameliorate
the abnormal expression profiles of inflammatory and oxi-
dative stress genes during endothelial injury in rats with a
Fig 7. Effects of ghrelin receptor antagonist and ginsenoside Rb1
on intracellular nitric oxide (NO) in human umbilical vein endo-
thelial cells (HUVECs) loaded with the NO-sensitive dye 4,5-
diaminofluorescein-2 diacetate (DAF-2 DA). A, HUVECs were
cultured for 48 hours in the following groups: control, Hcy, Rb1,
Hcy plus Rb1, Hcy plus Rb1 plus ghrelin receptor antagonist,
ghrelin receptor antagonist, then the intracellular NO contents
reflected by DAF-2DA fluorescence signal were observed. (a)
Control; (b) Hcy; (c) Rb1; (d) Hcy  Rb1; (e) Hcy  Rb1 
ghrelin receptor antagonist; and (f) ghrelin receptor antagonist.
The images were obtained by confocal laser microscopy, original
magnification 200. B, The bar chart shows the quantification of
mean DAF-2DA fluorescence intensity for intracellular NO. **P
.01 vs control group; ##P .01 vs Hcy group; P .05 vs Hcy
Rb1 group. Mean data are shown with the standard deviation.deficiency of vital energy, thereby protecting the vascular
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Volume 53, Number 1 Xu et al 163endothelium from injury.25 Ginsenoside Rb1 has also been
shown to enhance eNOS activity, promote NO release,
reduce reactive oxygen species production, and inhibit
endothelial proliferation and dysfunction induced by
Hcy.26,27 This study also found that eNOS protein expres-
sion was downregulated, NO production was reduced, and
vWF release, as a marker reflecting endothelial injury and
activation, was increased in HUVECs treated with Hcy.
However, these effects were all reversed by pretreatment
with 10 M ginsenoside Rb1, a dose that is consistent with
the dose referred to in a previous study.10
Ghrelin is the endogenous ligand for the growth hor-
mone secretagogue receptor (GHSR), which has an impor-
tant function in regulating secretion of growth hormone,
and circulating ghrelin is mainly synthesized and secreted
by the gastric mucosa.15 However, other tissues, such as
cardiac muscle, aorta, coronary artery, and pulmonary ar-
tery and vein, can also express ghrelin and its receptor.28
Ghrelin causes multiple cardiovascular protective effects,
including inhibition of inflammation, increase of cardiac
contractility and vascular relaxation, reduction of reactive
oxygen species production, and prevention of myocardial
cell apoptosis during cardiac ischemia.29
Shimizu et al30 found that ghrelin can exert its cardio-
vascular effects, including inhibition of endothelial death,
increase of eNOS expression in endothelial cells, direct
induction of NO synthesis, and improvement of endothe-
lial functions, in a growth hormone-independent manner.
Furthermore, ghrelin is the most potent endothelin-1
antagonist in vivo. In endothelium-deprived human inter-
nal mammary artery, ghrelin counteracted vasoconstriction
induced by the long-lasting vasoconstrictor endothelin-1,
suggesting that ghrelin can cause endothelium-independent
vasodilatation effects that may be mediated by multiple
factors.31 Studies have shown that ghrelin could improve
endothelial function, elevate the biologic activity of NO,
directly relax vascular smooth muscle, and suppress sympa-
thetic activity to reduce blood pressure through affecting
the central nervous system.32 Animal experiments have
indicated that plasma ghrelin content and ghrelin messen-
ger RNA in the aortic vascular tissue were decreased in rats
with angiosteosis, whereas after ghrelin treatment, calcifi-
cations of blood vessels and vascular cells were significantly
alleviated.33
It was reported that the plasma ghrelin level was signif-
icantly increased in heart failure patients with cachexia.34
We previously found that the ghrelin levels in the plasma
and myocardial tissues were compensatorily increased dur-
ing the pathologic course of Adriamycin-induced rat heart
failure, which protected the heart by protection of mito-
chondria, improvement of cardiac energy metabolism, en-
hancement of antioxidative capacity, and inhibition of
myocardial cell apoptosis.35,36 In this study, we found for
the first time that the plasma ghrelin level was significantly
elevated in the HHcy-induced endothelial injury rat model
compared with control, and that exogenous ghrelin can
evidently improve HHcy-induced endothelium-dependent
vasodilation dysfunction. This finding suggested that ele-vation of plasma ghrelin levels in the HHcy group might be
a compensatory and protective reaction to injury. A recent
study showed that ghrelin might prevent Hcy-induced
endothelial dysfunction in porcine coronary artery through
regulation of the eNOS/NO signaling pathway.9 This
study first found that ginsenosides may trigger the integral
ghrelin endocrine to protect the local vascular endothe-
lium, whether ginsenosides can upregulate the local expres-
sion of ghrelin and enhance its interaction with
ghrelin receptor (GHSR) in blood vessels has yet to be
determined.
Ghrelin is primarily secreted into the blood stream by
gastric X/A-like cells in the submucosal region. Approxi-
mately 60% to 70% of the ghrelin in circulation is derived
from the gastric mucosa, with a secondary contribution
from the small intestine. Other tissues of the body may also
produce a small amount of ghrelin. In this study, the
Hcy-induced compensatory elevation of the plasma ghrelin
level may be associated with the “relative scarceness” of
local ghrelin autocrine in the endothelial microenviron-
ment. Ginsenosides may regulate energy metabolism and
enhance the gastrointestinal ability to produce and secrete
more ghrelin into circulation. So, ginsenoside treatment
could significantly stimulate ghrelin endocrine. Normal
vascular endothelium can synthesize, activate, and release a
variety of active substances through metabolism. As the
largest endocrine store, it has an important function in
regulating vascular tone, hemostasis, antithrombosis, and
maintaining normal vascular functions by secretion of mul-
tiple active substances. It has been reported that rat and
human myocardial cells can synthesize and secrete ghrelin
to inhibit cell apoptosis in a paracrine/autocrine manner.37
In the present study, we found that normal endothelial cells
can function like the myocardial cells to express and secrete
ghrelin. Furthermore, when endothelial cells were injured,
the autocrine ghrelin level was significantly reduced, and
the ghrelin level was negatively correlated with the vWF
level. All these suggested that the autocrine ghrelin level
was associated with the degree of endothelial injury. In
addition, this study also showed that ghrelin levels secreted
by endothelial cells were positively correlated with NO
production.
CONCLUSIONS
Ginsenoside Rb1 protected endothelial cells through
upregulation of ghrelin secretion, NO production, and
eNOS protein expression, which was reduced by Hcy,
implying that ghrelin peptide mediated endothelial protec-
tion by ginsenoside Rb1 through regulating the NO sig-
naling pathway. This study provides a thought of seeking
both a temporary solution, such as exogenous ghrelin
treatment or surgery, and permanent cure with Chinese
herbs in clinical vascular diseases.
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